Clinical Trials Logo

Healthy Participants clinical trials

View clinical trials related to Healthy Participants.

Filter by:

NCT ID: NCT03031145 Withdrawn - Clinical trials for Healthy Participants

Investigation of the Impact of Smoking Status on Allergen-induced Nasal Airway Inflammation Using a Cat Hair (Felis Domesticus) Extract Nasal Allergen Challenge Model

Kitty Nose
Start date: April 3, 2017
Phase: Phase 1
Study type: Interventional

The purpose of this pilot study is to evaluate allergen-induced nasal airway inflammation following nasal application of felis domesticus, or cat, extract in e-cigarette users, cigarette smokers, and non-smokers.

NCT ID: NCT03007771 Withdrawn - Cervical Cancer Clinical Trials

Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia

Start date: September 30, 2017
Phase: Phase 1
Study type: Interventional

This study will help to elucidate the treatment sites in the extremities and pelvis for which MR-guided HIFU heating is feasible, which has the potential to be beneficial for patients with conditions at those sites (soft tissue sarcoma, cervical cancer, etc.). The investigators anticipate that successful completion of this study will lead to clinical trials in those feasible sites of interest to determine the safety and efficacy of administering therapeutic levels of heat for hyperthermia or other applications.

NCT ID: NCT02672371 Withdrawn - Clinical trials for Healthy Participants

The Effects of Sensory Training On Pain Modulation, Cognition and Time to Fatigue in Healthy Adults

Start date: June 2017
Phase: N/A
Study type: Interventional

The study is a randomized clinical trial that is assessing the effects of sensory training on pain modulation, cognition, and physical endurance (time to fatigue) in healthy participants

NCT ID: NCT01659177 Withdrawn - Clinical trials for Healthy Participants

A Study of LY2140023 in Healthy Participants

Start date: August 2012
Phase: Phase 1
Study type: Interventional

The study will evaluate the effect of food on absorption of LY2140023 in blood. This study involves a single dose of 80 mg LY2140023 taken as a tablet by mouth on 2 occasions, once on an empty stomach and once after eating breakfast. There is a minimum 3 day washout between doses. This study will last approximately 16 days not including screening. Screening is required within 30 days prior to the start of the study.